Oricell Therapeutics Closes $110 Million Pre-IPO Financing to Accelerate Global Development of Solid Tumor CAR-T Therapies

SHANGHAI, China, April 10, 2026 – Oricell Therapeutics Holdings Limited ("Oricell"), a global clinical-stage biotechnology company pioneering innovative cancer immunotherapies, today announced the closing of a pre-IPO financing round in excess of $110 million. The round was co-led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and a leading global healthcare fund. The syndicate included an international sovereign wealth fund, E-Town Capital, Luxin Venture Capital, NGS Super, Elikon Investment, and Talon Capital.

Proceeds will be strategically allocated to accelerate Oricell's global expansion and clinical development, while strengthening its technological capabilities and paving the way to upcoming capital market milestones.

As a frontrunner in cell therapy, OriCell is focused on engineering CAR-Ts with global clinical impact, having already secured confirmatory proof-of-concept (POC) data across multiple pipelines. By leveraging its proprietary triad: the Ori®Ab antibody screening and engineering platform, the Ori®Armoring functional enhancement platform, and the OnGo(Fast) rapid CMC manufacturing expertise, the company has built a differentiated portfolio that positions it at the vanguard of the global CAR-T race.

OriCell's lead asset, Ori-C101, is a GPC3-targeted autologous CAR-T therapy for advanced hepatocellular carcinoma (HCC). Having successfully navigated investigator-initiated trials (IIT) and a registrational Phase 1 study, the program is now gearing up for pivotal trials. Clinical readouts have demonstrated a best-in-class efficacy and safety profile, with data highlighted at major forums including the ASCO Annual Meeting. With these promising results, Ori-C101 is positioned to become the first-in-class CAR-T therapy approved globally for HCC.

Beyond its lead asset, Oricell is aggressively advancing a diverse portfolio of next-generation modalities, including secreted, rapid-production, and in vivo CAR-T programs.

Dr. Huanfeng Yang, Chairman and CEO of Oricell Therapeutics, stated: "This financing is a testament to the global potential of our science and the dedication of our team. As we approach key inflection points in our clinical programs, our priority is clear: expedite the global development of our core assets and deepening our research into revolutionary technologies, including in vivo CAR-T and solid tumor CAR-T. We are committed to delivering transformative therapies that offer real hope to cancer patients worldwide, positioning Oricell as a dominant force in the global immunotherapy arena."

Mr. Shan Fu, Managing Partner at Vivo Capital, commented:"While cell therapy is undoubtedly the future of oncology, solid tumors remain the industry's toughest nut to crack. Oricell distinguishes itself not just through best-in-class clinical data for its GPC3 CAR-T, but also through a pragmatic and visionary roadmap for next-generation modalities like in vivo CAR-T. We have high conviction in their integrated 'Platform and Pipeline' strategy and believe they are poised to set the new standard of care in the field. Vivo Capital is eager to deploy our global network to accelerate Oricell's expansion into international markets."

Mr. William Hu, Managing Partner at Qiming Venture Partners, stated: "As an early investor that has stood with Oricell since the Pre-A round, we have witnessed every milestone of its journey—from technological exploration to pipeline realization, and from local innovation to global expansion. We look forward to Oricell leveraging breakthrough cell therapy solutions and stronger clinical data to define the next generation of cancer care, bringing hope to patients worldwide."

About Oricell Therapeutics

Oricell is a clinical-stage biotechnology company developing next-generation cell therapies to address unmet needs in oncology and immunology. Powered by a proprietary technology triad: Ori®Ab (antibody discovery), Ori®Armoring (T-cell enhancement), and OnGo CMC (rapid manufacturing), Oricell has advanced a diversified pipeline targeting both solid tumors and hematologic malignancies. This technical prowess and global strategy are exemplified by the development of another core candidate, OriCAR-017. Supported by compelling data from IIT in China, the program paved the way into global development, rapidly securing IND approvals from both China NMPA and US FDA, along with FDA Orphan Drug Designation (ODD) and Fast Track Designation (FTD). OriCAR-017 has demonstrated a favorable safety profile and robust efficacy in both IIT and registrational clinical trials, with data featured at leading global conferences including 2022 ASCO, 2022 EHA, 2024 ASCO, and published in top-tier academic journals The Lancet Haematology. These milestones underscore Oricell's capabilities in regulatory strategy, clinical development, and global execution, reflecting its commitment to transforming the future of cell therapy and delivering new hope to patients worldwide. For more information, please visit: **www.oricell.com**.

About Vivo Capital

Vivo Capital is a premier global healthcare investment firm with a 30-year track record of building transformative companies. Since its founding in 1996, Vivo has evolved into a comprehensive investment platform spanning venture capital, growth equity, buyouts, and public markets. Managing $7.5 billion in assets across 16 USD and RMB funds, the firm has cultivated a portfolio of over 460 innovative companies worldwide. Vivo's strategy goes beyond capital; it leverages a deeply integrated ecosystem to provide strategic operational support and resource connectivity to its partners. With an exclusive focus on the healthcare sector—ranging from biotech and pharma to devices and services—Vivo targets high-growth opportunities in the world's most critical markets. Headquartered in Palo Alto, California, Vivo operates with a lean, expert team of over 70 professionals, maintaining key hubs in Beijing, Shanghai, Hong Kong, Taipei, and Singapore to bridge global innovation with local execution.

About Beijing Medical and Health Care Industry Investment Fund

Beijing Medical and Health Care Industry Investment Fund is managed by Beijing Shunxi Private Fund Management Co., Ltd. ("Shunxi Fund"), a full-lifecycle investment platform under Beijing State-owned Capital Operation and Management Co., Ltd. (BSCOMC). Shunxi Fund focuses on strategic emerging sectors—particularly biopharma and healthcare—and has evolved from its original mandate of "investing early, small, in technology, and in Beijing" into a comprehensive investor across the innovation lifecycle. Through partnerships with top universities, research institutes, municipal/state-owned funds, leading industry players, government agencies, and market-driven GP collaborators, Shunxi has built a multi-dimensional ecosystem that delivers unique deal flow and robust post-investment value creation.

About Qiming Venture Partners

Qiming Venture Partners was founded in 2006. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Healthcare industries at the early and growth stages. Since our debut, we have backed over 580 fast-growing and innovative companies. Over 210 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 80 portfolio companies that have achieved unicorn or super unicorn status.

About E-Town Capital

E-Town Capital is a leading state-owned investment platform dedicated to advancing Beijing's economic development through strategic investments in high-growth sectors. The firm focuses on biotechnology and healthcare, next-generation information technology, new energy intelligent vehicles, and robotics, operating across four core business lines: industrial investment, fund management, technology finance, and IT infrastructure innovation.

As of September 2025, E-Town Capital manages over 90 funds with RMB 60 billion in paid-in capital and a total fund size exceeding RMB 1 trillion, supporting 280+ investment projects across Beijing's innovation ecosystem. Its portfolio drives technological advancement while directly contributing to the city's strategic economic goals.

About Luxin Venture Capital

Luxin Venture Capital Group Co., Ltd. (SHSE: 600783) stands as a dominant force in China's private equity landscape. Controlled by the state-owned Shandong Luxin Investment Holding Group, Luxin holds the distinction of being the first venture capital firm to list on mainland China's domestic capital markets. Over its two-decade history, the firm has scaled its operations significantly, currently managing more than 40 funds with approximately 20 billion yuan ($2.8 billion) in assets under management. Its investment thesis targets high-growth sectors critical to China's economic transition, including healthcare, advanced manufacturing, electronics, new energy, and new materials.

About Elikon Venture

Founded in 2021, Elikon Venture is a specialized early-stage venture firm focused exclusively on biomedical innovation. The firm partners with entrepreneurs developing proprietary IP and globally competitive technologies to address unmet clinical needs, accelerating the development of therapeutics that deliver measurable clinical outcomes and improve patient health.

About Talon Capital

Headquartered in Hong Kong, Talon Capital is the private equity investment division of Wealth Harbour Investment & Management Co., Limited, an SFC licensed corporation in Hong Kong. It invests in core sectors including technology, healthcare, business services and consumer in Asia across the company lifecycle primarily from growth to mid-market stage. By adhering to an investment philosophy that places company quality at the center and a founder-to-founder approach at the heart of value creation, Talon Capital partners with outstanding businesses to drive sustainable growth and achieve superior return.

原启生物宣布累计完成 1.1 亿美元 Pre-IPO 轮融资，加速实体肿瘤 CAR-T 全球开发进程

中国上海，2026 年 4 月 10 日 —— 全球创新肿瘤免疫疗法领军企业 Oricell Therapeutics Holdings Limited（下称“原启生物”或“Oricell”或“公司”）今日正式宣布累计完成 1.1 亿美元的 Pre-IPO 轮融资。本轮融资由维梧资本、北京市医药健康产业投资基金、启明创投及一家全球领先的医疗基金共同领投，某国际主权基金、亦庄国投、鲁信创投、NGS（澳大利亚养老基金）、骊宸投资、瑞锋资本等知名机构跟投。本轮融资所得资金将主要用于加速原启生物的国际化战略布局，推动核心管线的全球多中心临床开发，进一步夯实其在细胞治疗领域的技术壁垒，并加速产业化管线的价值释放，为即将到来的资本市场里程碑做好充分准备。

作为细胞治疗药物领域的领军企业，原启生物始终致力于开发具有全球临床价值的 CAR-T 细胞疗法，并已在多条管线上取得了确证性的概念验证（POC）临床数据。依托公司自主创新的 Ori®Ab 抗体筛选与工程平台、Ori®Armoring 结构增强平台及 OnGo(Fast) CMC 快速工艺专长，原启生物成功构建了差异化的产品管线，在全球 CAR-T 技术竞争中占据高地。

原启生物的核心产品包括 Ori-C101，一款靶向 GPC3、用于治疗晚期肝细胞癌（HCC）的自体 CAR-T 药物。该产品已完成研究者发起的临床试验（IIT）及注册临床 I 期试验，即将启动关键性临床试验。已读出的临床数据展现出优异的有效性和安全性特征，相关成果多次在 ASCO（美国临床肿瘤学会年会）等国际顶级学术会议上发表。凭借目前积极的临床进展，Ori-C101 有望成为全球首款获批上市的针对肝细胞癌的 CAR-T 药物。

除核心管线外，原启生物的全平台技术体系正持续孵化多个下一代多靶点、多机制的 CAR-T 产品，包括分泌型、快速生产型和多款 in vivo CAR-T 项目。

原启生物董事长兼首席执行官杨焕凤博士表示：“非常感谢各位投资人对公司愿景与技术实力的高度认可。本轮融资是原启生物发展历程中的重要里程碑。我们将持续聚焦核心管线的全球临床推进，深化 in vivo CAR-T 和实体瘤 CAR-T 等革命性技术的研发，充分利用公司在技术积累、政策环境及市场需求方面的多重优势，加快临床阶段产品的开发速度、降低成本、增加可及性。我们的目标是用更具突破性的细胞治疗方案，为全球肿瘤患者带来新的治愈希望，稳步迈向全球领先免疫治疗企业的行列。”

维梧资本管理合伙人付山先生表示：“细胞治疗是未来肿瘤治疗的基石，而实体瘤一直是该领域亟待攻克的堡垒。原启生物不仅在 GPC3 靶点上展现了全球领先的临床数据，更在 in vivo CAR-T 等下一代技术上进行了前瞻性且务实的布局。维梧资本看好原启生物‘平

台+管线’双轮驱动的模式，相信其有能力成为定义下一代细胞治疗标准的全球性企业。我们期待利用维梧的全球生态资源，助力原启生物加速国际化进程。”

北京顺禧私募基金管理有限公司董事长、总经理任鹏先生表示：“我们认为细胞治疗是攻克实体瘤的重要方向，原启生物 GPC3 CAR-T 在治疗肝癌上的临床进展让我们非常惊喜。我们高度认可团队的研发实力与商业化视野，期待本轮融资助力公司加速核心产品的全球临床突破。”

启明创投主管合伙人胡旭波先生表示：“作为原启生物从 Pre-A 轮起就一路陪伴的早期投资方，我们见证了公司从技术探索到管线落地以及临床进展、从本土创新到全球布局的每一步跨越。我们期待原启生物用突破性的细胞治疗方案，更好的临床数据，成就下一代肿瘤治疗，为全球肿瘤患者传递治愈希望。”

关于原启生物

原启生物是一家临床阶段的生物技术公司，致力成为创新驱动的全球领先肿瘤免疫疗法开拓者，目前专注开发创新型细胞疗法，以解决全球肿瘤学和免疫学领域未被满足的医疗需求。通过自主创新的 Ori®Ab 抗体筛选和工程平台、Ori®Armoring 结构增强平台及 OnGo(Fast)CMC 领域积累的专识，公司构建了高效协同的技术引擎，并成功开发出多条治疗实体肿瘤和血液肿瘤的产品管线。这一强大的技术实力与全球化战略在另一款核心产品 OriCAR-017 的开发进程中得到了充分验证。该项目始于中国的研究者发起临床试验（IIT），凭借卓越的早期数据奠定了国际化基础，随后迅速获得中国 NMPA 和美国 FDA 的 IND 批准，并得到了 FDA ODD 孤儿药资格以及 FTD 快速审评资格认定。其探索性临床研究及注册临床均验证出良好的安全性和有效性，相关成果入选 2022 ASCO、2022 EHA、2024 ASCO 年会口头报告，并发表于《柳叶刀血液学》等国际权威学术期刊，彰显了公司强大的注册法规、技术转化、临床开发以及全球布局能力。原启生物始终致力于通过创新技术推动细胞治疗领域的发展，为全球肿瘤患者带来新的希望。了解更多信息，请访问官网：www.oricell.com。

关于维梧资本

维梧资本（Vivo Capital）成立于 1996 年，是一家全球领先的医疗健康投资机构，致力于通过生态策略实现战略赋能和资源整合。维梧资本在风险投资、成长型和控股型私募股权以及公开市场拥有多基金投资平台，累计管理 16 支美元基金和人民币基金，积极在管资产规模超过 75 亿美元，在全球范围内布局超过 460 家企业。旗下所有基金均广泛投资于医疗健康领域，包括生物技术、制药、医疗器械和医疗服务等，重点关注全球最大的医疗健康市场。维梧资本拥有一支由 70 余名专业人士组成的团队，总部位于美国加州帕洛阿尔托，在北京、上海、香港、台北和新加坡均设有办公室。

关于北京市医药健康产业投资基金

北京市医药健康产业投资基金由北京顺禧私募基金管理有限公司（“顺禧基金”）管理。顺禧基金是北京国管旗下全生命周期投资平台，重点聚焦战略性新兴产业投资。自成立以来，顺禧管理公司由定位为北京国管旗下“投早、投小、投科技、投北京”的创投平台逐步成长为全生命周期投资平台，通过与多家高校院所、新型研发机构、市区两级国资基金、市场化合作 GP、产业链主企业、政府主管部门建立良好合作关系，不断打造多维度协同支撑体系，积累了优势独特、渠道多元的优质项目资源和投后赋能能力。

关于启明创投

启明创投成立于 2006 年。目前，启明创投旗下管理 11 只美元基金，7 只人民币基金，已募管理资产总额达到 95 亿美元。自成立至今，专注于投资科技(Technology)、医疗健康(Healthcare)等行业早期和成长期的优秀企业。截至目前，启明创投已投资超过 580 家高速成长的创新企业，其中有超过 210 家分别在美国纽交所、纳斯达克，香港交易所，上交所及深交所等交易所上市，或通过并购等方式退出，有 80 多家企业成为行业公认的独角兽或超级独角兽企业。

关于某国际主权财富基金

2005 年成立，负责投资和管理国家储备基金,是全球最大、最活跃的主权财富基金之一。其投资于多种资产类别和区域，并与世界各地的领先机构结成伙伴关系，以建立一个具有长期前景的全球多元化投资组合，从而实现可持续回报。

关于亦庄国投

北京亦庄国际投资发展有限公司（下称“亦庄国投”）是一家以促进北京产业发展和科技创新为使命的国有资本投资运营公司。亦庄国投紧紧围绕“专业化、市场化、价值化的产业赋能型投资平台”功能定位，聚焦新一代信息技术、生物技术和大健康、新能源智能汽车、机器人和智能制造四大产业，深耕产业投资、基金管理、科技金融、信创基地四大主业，积极助力北京“四个中心”功能建设。截至 2025 年 9 月底，亦庄国投资产总额超 1400 亿元，在管投资项目超 280 个。在管基金 90 余支，实缴出资超 600 亿元，基金总规模超万亿元。

关于鲁信创投

鲁信创业投资集团股份有限公司（股票代码：600783）是中国私募股权领域的一支主导力量。由国有独资企业山东省鲁信投资控股集团有限公司控股，鲁信创投拥有独特的市场地位——它是首家在中国内地资本市场上市的创投机构。

在二十多年的发展历程中，该公司规模显著扩大，目前管理着 40 多支基金，资产管理规模约 200 亿元人民币（约合 28 亿美元）。其投资策略聚焦于对中国经济转型至关重要的高增长赛道，涵盖医疗健康、先进制造、电子信息、新能源及新材料等领域。

关于骊宸投资

骊宸投资成立于 2021 年，是一家专注于创新生物医药领域早期投资的专业机构。以满足临床刚性需求为出发点，骊宸投资期望携手拥有独立知识产权及全球领先技术的企业和企业家，与之共同成长，开发出可以实现临床获益的产品及方案，造福于病人和社会。

关于瑞锋资本

瑞锋资本是香港证监会持牌机构财富港湾旗下的私募股权投资机构，专注于大中华地区成长阶段至中型市场阶段的优秀企业。通过聚焦核心板块，秉承以企业质量为核心准则、以支持管理团队为核心赋能的理念，通过资本与战略资源赋能，陪伴企业实现可持续成长与长期价值提升。